DK1406898T3 - Substituerede piperazinforbindelser og anvendelse af disse som fedtsyreoxidationsinhibitorer - Google Patents

Substituerede piperazinforbindelser og anvendelse af disse som fedtsyreoxidationsinhibitorer

Info

Publication number
DK1406898T3
DK1406898T3 DK02756522T DK02756522T DK1406898T3 DK 1406898 T3 DK1406898 T3 DK 1406898T3 DK 02756522 T DK02756522 T DK 02756522T DK 02756522 T DK02756522 T DK 02756522T DK 1406898 T3 DK1406898 T3 DK 1406898T3
Authority
DK
Denmark
Prior art keywords
fatty acid
acid oxidation
oxidation inhibitors
substituted piperazine
angina
Prior art date
Application number
DK02756522T
Other languages
English (en)
Inventor
Kevin Shenk
Elfatih Elzein
Jeff Zablocki
Kenneth Rehder
Prabha Ibrahim
Venkata Palle
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of DK1406898T3 publication Critical patent/DK1406898T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57Aryl or substituted aryl radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Lubricants (AREA)
  • Paper (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK02756522T 2001-07-19 2002-07-18 Substituerede piperazinforbindelser og anvendelse af disse som fedtsyreoxidationsinhibitorer DK1406898T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30662101P 2001-07-19 2001-07-19
PCT/US2002/022897 WO2003008411A1 (en) 2001-07-19 2002-07-18 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors

Publications (1)

Publication Number Publication Date
DK1406898T3 true DK1406898T3 (da) 2005-05-30

Family

ID=23186103

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02756522T DK1406898T3 (da) 2001-07-19 2002-07-18 Substituerede piperazinforbindelser og anvendelse af disse som fedtsyreoxidationsinhibitorer

Country Status (22)

Country Link
US (1) US6930111B2 (da)
EP (1) EP1406898B1 (da)
JP (1) JP2004537554A (da)
KR (1) KR100919141B1 (da)
CN (1) CN1533388A (da)
AT (1) ATE292633T1 (da)
AU (1) AU2008202958A1 (da)
CA (1) CA2454059A1 (da)
DE (1) DE60203623T2 (da)
DK (1) DK1406898T3 (da)
ES (1) ES2236557T3 (da)
HK (1) HK1064374A1 (da)
HU (1) HUP0402088A3 (da)
IL (1) IL159897A0 (da)
MX (1) MXPA04000565A (da)
NO (1) NO327635B1 (da)
NZ (1) NZ530705A (da)
PL (1) PL368529A1 (da)
PT (1) PT1406898E (da)
RU (1) RU2300533C2 (da)
WO (1) WO2003008411A1 (da)
ZA (1) ZA200400404B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001909B2 (en) * 2001-07-19 2006-02-21 Cv Therapeutics, Inc. Substituted heterocyclic compounds
CA2486712C (en) * 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
MXPA05001592A (es) * 2002-08-09 2005-05-05 Astrazeneca Ab Oxadiazoles como moduladores de receptor-5 de glutamato metabotropico.
WO2004014881A2 (en) 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
CA2495179A1 (en) 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
CA2508608A1 (en) * 2002-12-05 2004-06-24 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
EP1806346B1 (en) * 2002-12-05 2009-07-22 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
CA2512261A1 (en) 2003-01-03 2004-07-29 Cv Therapeutics, Inc. Substituted heterocyclic compounds
AU2004209522A1 (en) * 2003-01-17 2004-08-19 Gilead Palo Alto, Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
CA2530376A1 (en) * 2003-06-23 2005-01-06 Cv Therapeutics, Inc. Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors
US7115610B2 (en) 2003-12-18 2006-10-03 Cv Therapeutics, Inc. Substituted heterocyclic compounds
US7959659B2 (en) * 2004-01-02 2011-06-14 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
AU2005282492A1 (en) * 2004-09-08 2006-03-16 Gilead Palo Alto, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
WO2008023248A2 (en) 2006-08-24 2008-02-28 Wockhardt Research Centre Novel macrolides and ketolides having antimicrobial activity
US8088920B2 (en) * 2008-03-31 2012-01-03 Hoffmann-La Roche Inc. 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
PT3135672T (pt) 2008-10-10 2020-04-02 Vm Discovery Inc Composições e métodos para o tratamento distúrbios de utilização de álcool, dor e outras doenças
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
WO2011115150A1 (ja) * 2010-03-18 2011-09-22 興和株式会社 ベンゾチアジン化合物の製造方法
CN111285819A (zh) * 2018-12-07 2020-06-16 江苏恩华药业股份有限公司 一种苯并噁唑类化合物及其应用
WO2023023995A1 (zh) * 2021-08-25 2023-03-02 苏州大学 一种防治心肌缺血后心功能衰竭的药物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1133989A (en) * 1964-12-08 1968-11-20 Chugai Pharmaceutical Co Ltd Theophylline derivatives, their salts and process for preparing the same
DE2834114A1 (de) * 1978-08-01 1980-02-14 Schering Ag Polyalkoxyphenylpyrrolidone iii, verfahren zu ihrer herstellung und ihre verwendung
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
JPS6137765A (ja) * 1984-07-19 1986-02-22 サンド・アクチエンゲゼルシヤフト 3‐アミノプロポキシアリール誘導体
US4723014A (en) * 1986-11-19 1988-02-02 Warner-Lambert Company Process for the preparation of 2-substituted-1,4-dihydropyridines
DE3723648A1 (de) * 1987-07-17 1989-01-26 Sandoz Ag Indol-derivate, ihre herstellung und sie enthaltende arzneimittel
JPH0699399B2 (ja) * 1988-10-06 1994-12-07 三井東圧化学株式会社 新規複素環化合物およびそれを有効成分として含有する製癌剤効果増強剤
JPH02268162A (ja) * 1989-04-10 1990-11-01 Fujisawa Pharmaceut Co Ltd ジフェニルピリジン誘導体
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
WO1998021190A1 (en) * 1996-11-14 1998-05-22 American Home Products Corporation Substituted tetrahydro-1,3,5-triazin-2[1h]-thiones as anti-atherosclerotic agents
CN1196708C (zh) * 1999-09-13 2005-04-13 惠氏公司 2-(4-羟基-苯基)-1-[4-(2-氨-1-基-乙氧基)-苄基]-1h-吲哚-5-酚的吡喃葡糖苷轭合物
SE9904765D0 (sv) * 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
JP3980885B2 (ja) * 2000-02-22 2007-09-26 スィーヴィー セラピューティクス インコーポレイテッド 置換ピペラジン化合物
US6451798B2 (en) * 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
US6638970B2 (en) * 2000-02-22 2003-10-28 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
AU2001238590A1 (en) * 2000-02-22 2001-09-03 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
SE0003795D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives

Also Published As

Publication number Publication date
ZA200400404B (en) 2004-10-14
EP1406898A1 (en) 2004-04-14
IL159897A0 (en) 2004-06-20
KR20040029374A (ko) 2004-04-06
AU2002322527B2 (en) 2008-04-17
DE60203623T2 (de) 2006-01-19
AU2002322527A2 (en) 2003-03-03
DE60203623D1 (de) 2005-05-12
CA2454059A1 (en) 2003-01-30
PL368529A1 (en) 2005-04-04
PT1406898E (pt) 2005-08-31
RU2300533C2 (ru) 2007-06-10
ATE292633T1 (de) 2005-04-15
WO2003008411A1 (en) 2003-01-30
US20030181352A1 (en) 2003-09-25
RU2004104951A (ru) 2005-06-27
EP1406898B1 (en) 2005-04-06
KR100919141B1 (ko) 2009-09-25
AU2008202958A1 (en) 2008-07-31
HUP0402088A2 (hu) 2005-02-28
NO20040234L (no) 2004-03-18
ES2236557T3 (es) 2005-07-16
HUP0402088A3 (en) 2010-03-29
NZ530705A (en) 2005-08-26
HK1064374A1 (en) 2005-01-28
JP2004537554A (ja) 2004-12-16
CN1533388A (zh) 2004-09-29
MXPA04000565A (es) 2005-06-17
US6930111B2 (en) 2005-08-16
NO327635B1 (no) 2009-09-07

Similar Documents

Publication Publication Date Title
DK1406898T3 (da) Substituerede piperazinforbindelser og anvendelse af disse som fedtsyreoxidationsinhibitorer
NO20054969L (no) 2-cyanopropansyreamid- og esterderivater og deres anvendelse
ATE411288T1 (de) Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
NO20053627L (no) Malonamidderivater som gamma-sekretase inhibitorer
NO20023879L (no) Partielle fettsyre-oksydasjonsinhibitorer i behandlingen av kongestiv hjertesvikt
BR0114045A (pt) Poliarilcarboxamidas úteis como agentes redutores de lipìdeos
NO20051965D0 (no) Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
NO20060314L (no) Nicotinamid-derivater anvendbare som PDE4-inhibitorer
EA200400223A1 (ru) Новые производные 2h-пиридазин-3-она, фармацевтические композиции, содержащие эти производные, и способ получения активного ингредиента
DE60105419D1 (de) Serinprotease-inhibitoren
CY1106969T1 (el) Αναστολεις dpp-iv
ATE311380T1 (de) Durch säuregruppen disubstitierte heteroaryl- derivate und ihre verwendung als matrix metalloproteinas inhibitoren
EE200200203A (et) Südame arütmia ravis kasutatavad uued oksabispidiinühendid
DK1569900T3 (da) Substituerede 3-carbonyl-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
SE0100326D0 (sv) New compounds
ATE370934T1 (de) Substituierte dihydrophenanthridin-sulfonamide
HK1111683A1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
NO20023001L (no) Substituerte piperazinderivater som MTP inhibitorer
UY27074A1 (es) Derivados de aminotriazolopiridina
WO2004067506A3 (en) Substituted heterocyclic compounds
DE60329323D1 (de) Substituierte heterozyklische verbindungen
BR0314461A (pt) Processo para a preparação de derivado de 2-aminometilpiridina
SE0003795D0 (sv) Pharmaceutically useful compounds